Collegium Pharmaceutical (COLL) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Collegium Pharmaceutical (NASDAQ: COLL) recently:

• 8/19/2026 – Collegium Pharmaceutical had its price target lowered by Barclays PLC from $56.00 to $48.00. They now have an “overweight” rating on the stock.
• 8/11/2026 – Collegium Pharmaceutical was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 8/8/2026 – Collegium Pharmaceutical was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/7/2026 – Collegium Pharmaceutical had its “neutral” rating reaffirmed by Piper Sandler. They now have a $43.00 price target on the stock, down from $45.00.
• 8/6/2026 – Collegium Pharmaceutical had its price target lowered by Needham & Company LLC from $56.00 to $46.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Collegium Pharmaceutical was downgraded by Zacks Research from “strong-buy” to “hold”.
• 7/25/2026 – Collegium Pharmaceutical was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/6/2026 – Collegium Pharmaceutical had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 6/29/2026 – Collegium Pharmaceutical was upgraded by Zacks Research from “hold” to “strong-buy”.

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.